LONDON: AstraZeneca PLC said Tuesday that a European patent covering the use of its Symbicort medicine as a treatment for a condition commonly known as “smoker’s cough” has been revoked.
LONDON: AstraZeneca PLC said Tuesday that a European patent covering the use of its Symbicort medicine as a treatment for a condition commonly known as “smoker’s cough” has been revoked.
